Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent grant is significant because it strengthens Greenland Mines’ position in the emerging field of gene therapy for neurodegenerative diseases. Klotho is a protein associated with longevity and cognitive function, and its gene therapy applications could offer new treatment avenues for conditions with high unmet medical needs. The Canadian patent provides exclusivity in a key market, potentially enabling the company to secure partnerships or funding for clinical development. Additionally, the advancement of KLTO-202 to GMP manufacturing indicates progress toward clinical trials, which could be a catalyst for the company’s biotech division.
Greenland Mines operates two divisions: mining and biotech. The mining division focuses on the Skaergaard Project in Greenland and the Sarfartoq rare earths project. The biotech division includes Klotho-based therapies, with KLTO-202 targeting ALS. The company’s strategy is to build a multi-asset platform with exposure to rare earth magnet materials and precious metals while advancing its North Atlantic Critical Metals Corridor vision. The patent news may attract investor attention to the biotech segment, which could diversify the company’s risk profile.
For more details, the full press release is available at https://ibn.fm/x2pHA. Information about Greenland Mines can be found at https://ibn.fm/GRML.
